Pharmacology of P2Y receptors.

P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. There are eight mammalian P2Y receptor subtypes divided into two subgroups (P2Y ₁ , P2Y ₂ , P2Y ₄ , P2Y ₆ , and P2Y ₁₁ ) and (P2Y ₁₂ , P2Y ₁₃ , and P2Y ₁₄ ). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain. The antagonism of P2Y ₁₂ receptors is used in pharmacotherapy for the prevention and therapy of cardiovascular events. The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y ₁₂ receptors and reduce thereby platelet aggregation. The P2Y ₂ receptor agonist diquafosol is used for the treatment of the dry eye syndrome. The P2Y receptor subtypes differ in their amino acid sequences, their pharmacological profiles and their signaling transduction pathways. Recently, selective receptor ligands have been developed for all subtypes. The published crystal structures of the human P2Y ₁ and P2Y ₁₂ receptors as well as receptor models will facilitate the development of novel drugs for pharmacotherapy.
(Copyright © 2019 Elsevier Inc. All rights reserved.)